Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
This study, called a "Natural History Study," aims to gather information about children and young people up to 18 who have a heart condition known as cardiomyopathy. This specific type of cardiomyopathy is linked to a fault in a gene called MYBPC3. Researchers want to understand more about how the condition progresses over time, its effects on daily life, common risk factors, and the overall quality of life for those affected. They are also interested in learning about the different treatments, procedures, and long-term outcomes for these children. The study will collect information from existing medical records and, in some cases, follow children over time.
En un coup d'œil
De quoi parle cette étude ?
This study is called a "natural history study." Think of it like watching how a plant grows from a seed – it's about understanding how a condition develops and changes over time, without trying new treatments. Here, researchers are focusing on a particular heart condition in children and young people (up to 18 years old) called cardiomyopathy.
Cardiomyopathy means the heart muscle is abnormal, which can make it harder for the heart to pump blood effectively. In this study, they are specifically looking at cases where the cardiomyopathy is caused by a change (a 'mutation') in a gene called MYBPC3. Genes are like the instructions in our body, and a change in this gene can affect how the heart muscle works.
The main goal is to collect detailed information from existing medical records of children with this specific genetic change. They want to learn about how the condition affects daily life, what treatments have been used, and how children are doing long-term. This information is really important because it helps doctors and scientists understand the condition better, which can lead to better care and potentially new treatments in the future. They are also looking at whether there are particular things that make the condition worse or better, and how it impacts a child's quality of life.
Points clés
- This study focuses on children and young people (under 18) with a specific heart condition.
- The heart condition (cardiomyopathy) is linked to a fault in the MYBPC3 gene.
- It's a 'natural history' study, meaning it observes how the condition develops over time.
- The study primarily collects information from existing medical records.
- No new treatments or tests will be given as part of this study.
- The goal is to improve understanding and future care for children with this condition.
Qui peut être éligible ?
To be considered for this study, children and young people must be under 18 years old. They need to have had a genetic test that confirmed a change in their MYBPC3 gene, which is known to cause heart problems.
For information taken from past medical records, the child must have been under 18 when the information was recorded or when they passed away. There's a special rule for very young babies with two copies of the faulty gene where older records can be included.
For new information being collected (going forward), children also need to be under 18 and have the MYBPC3 gene change. They must also have been diagnosed with cardiomyopathy. If a child is already taking part in another study where a new treatment is being tested, they might not be able to join this one unless specific approval is given. Also, if a child has another serious illness that is expected to significantly shorten their life, they would not be eligible.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Is my child under 18 years old?
- Has my child had a genetic test showing a faulty MYBPC3 gene?
- Has my child been diagnosed with cardiomyopathy?
- Is my child currently not in another clinical trial testing a new treatment?
- Does my child not have any other severe illnesses that greatly shorten life expectancy?
En quoi consiste la participation ?
This study primarily involves collecting information from your child's existing medical records. This means researchers will look at past details about their condition, treatments they've received, and how they progressed. For some children, especially very young infants with specific gene changes or those joining the study currently, there might also be a plan to collect new information ongoingly. This would involve following your child's health and treatment over time through their regular medical appointments and records. You would not need to attend extra visits or take any new experimental medication for this study. The total duration of participation for those followed over time would depend on the study plan and your child's medical care, but it focuses on gathering routine medical data.
Risques et avantages potentiels
Locations (29)
- Hôpital pour enfants de l'ArkansasCode postal vérifiéLittle Rock, États-Unis
- Hôpital pour enfants de Los AngelesCode postal vérifiéLos Angeles, États-Unis
- University of California Davis HealthCode postal vérifiéSacramento, États-Unis
- Rady Children's Hospital - San DiegoCode postal vérifiéSan Diego, États-Unis
- University of Colorado Hospital - Anschutz Medical CampusCode postal vérifiéAurora, États-Unis
- Nemours Alfred I. Dupont Hospital for ChildrenCode postal vérifiéWilmington, United States
- Joe DiMaggio Children's HospitalCode postal vérifiéHollywood, États-Unis
- Children's Mercy Hospital KansasCode postal vérifiéKansas City, États-Unis
- St. Louis Children's HospitalCode postal vérifiéSaint Louis, États-Unis
- Cohen Children's Medical CenterCode postal vérifiéLake Success, United States
- Mount SinaiCode postal vérifiéNew York, États-Unis
- Columbia University Irving Medical CenterCode postal vérifiéNew York, États-Unis
Questions fréquentes
What is cardiomyopathy?
Cardiomyopathy is a heart condition where the heart muscle is abnormal, which can make it harder for the heart to pump blood effectively around the body.
What does 'MYBPC3 mutation' mean?
It means there's a change or fault in a specific gene called MYBPC3. This gene gives instructions for making a protein important for heart muscle function, and a fault can cause heart problems.
Will my child receive new treatment in this study?
No, this study is about collecting information on how the condition develops and existing treatments. Your child will not receive any new or experimental treatments as part of this study.
Who can take part in this study?
Children and young people under 18 who have cardiomyopathy caused by a specific MYBPC3 gene fault are generally eligible. Eligibility depends on whether old records are being reviewed or new information is being collected.
What happens with the information collected?
The information helps doctors and researchers learn more about how this specific heart condition affects children, what treatments work best, and how it impacts their quality of life. This knowledge can lead to better care for children in the future.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.